Quintrio
Home

PHARMACEUTICAL PREPARATIONS

ADC Therapeutics SA

ADCT

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Last trade $1.39
Day change +$0.14 (+11.20%)
Day range $1.25 – $1.42
Volume 543,068
Market cap $176M

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$175.83M
Price / earnings
—
Price / book
-0.71×
Price / sales
2.07×
EV / sales
1.21×
EV / EBITDA
-1.27×

Profitability

Earnings per share
-$0.58
Return on assets
-31.75%
Return on equity
32.61%
Dividend yield
0%

Liquidity and leverage

Debt / equity
-0.47×
Current ratio
3.05×
Quick ratio
2.98×
Cash ratio
2.42×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$100.55M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ADCT, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$21.72M$19.25M$20.85M$23.06M$16.43M$18.84M$23.03M$16.91M
Cost of revenue$1.98M$2.35M$3.62M$1.7M$1.2M$836K$2.06M$1.37M
Gross profit$19.74M$16.9M$17.24M$21.36M$15.23M$18M$20.97M$15.54M
Selling, general and administrative$19.41M$22.27M$22.6M$21.44M$19.01M$18.97M$20.51M$20.87M
Research and development$14.74M$17.37M$19.88M$18.18M$26.8M$30.09M$28.93M$27.1M
Total operating expenses$34.09M$42.31M$42.48M$39.28M$46.19M$62.15M$49.44M$47.98M
Operating income-$14.35M-$25.41M-$25.25M-$17.92M-$30.97M-$44.15M-$28.46M-$32.44M
Interest expense-$13.73M-$13.51M-$12.35M-$13.01M-$13.39M-$13M-$12.23M-$11.92M
Income before taxes-$25.3M-$16.57M-$32.97M-$6.81M-$40.97M-$55.39M-$38.44M-$32.59M
Income taxes$0$0$0-$404K$0$1.25M$165K-$321K
Net income-$25.3M-$16.57M-$32.97M-$6.41M-$40.97M-$56.65M-$38.6M-$30.73M
Net income attributable to common shareholders-$25.3M-$16.57M-$32.97M-$6.41M-$40.97M-$56.65M-$38.6M-$30.73M
EBITDA-$14.41M-$22.74M-$25.25M-$18.27M-$30.59M-$31.06M-$28.46M-$32.1M
Basic earnings per share-$0.16-$0.11-$0.21-$0.04-$0.30-$0.50-$0.36-$0.29
Diluted earnings per share-$0.16-$0.11-$0.21-$0.04-$0.30-$0.50-$0.36-$0.29

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

ADC Therapeutics SA (ADCT) Reports Q3 Loss, Tops Revenue Estimates

ADC Therapeutics (ADCT) reported a quarterly loss of $0.16 per share, beating consensus estimates of $0.21 loss, with a 23.81% earnings surprise. Revenue of $21.72 million also exceeded expectations by 5.67%. However, the stock has declined 55.2% year-to-date versus the S&P 500's 7.8% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.

Zacks Investment Research

BioAge Labs, Inc. (BIOA) Reports Q3 Loss, Misses Revenue Estimates

BioAge Labs (BIOA) reported a quarterly loss of $0.73 per share, missing consensus estimates by 7.35%, with revenues of $0.3 million falling 66.89% short of expectations. The company's stock has declined 55% year-to-date, and it received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revisions. The Medical - Biomedical and Genetics industry ranks in the top 45% of sectors.

Zacks Investment Research

NeoGenomics (NEO) Q3 Earnings and Revenues Beat Estimates

NeoGenomics reported Q3 2026 earnings of $0.07 per share, beating consensus estimates of $0.06, with revenues of $209.25 million slightly exceeding expectations. The company has outperformed the market by 46.9% year-to-date. However, the stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. ADC Therapeutics is expected to report a quarterly loss of $0.21 per share.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
May 10, 20051-for-7reverse split